Financial

ARCA biopharma Announces Second Quarter 2018 Financial Results and Provides Corporate Update

WESTMINSTER, Colo., Aug. 09, 2018 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended June 30, 2018. “The second quarter of this year saw an important milestone for the […]

BioCardia, Inc. Reports Second Quarter 2018 Financial Results and Business Highlights

SAN CARLOS, Calif., Aug. 9, 2018 /PRNewswire/ — BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the second quarter 2018 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2018 with […]

Neovasc Announces Second Quarter 2018 Financial Results

VANCOUVER, Aug. 8, 2018 /PRNewswire/ – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today reported financial results for the second quarter ended June 30, […]

Boston Scientific Announces Agreement to Acquire VENITI, Inc.

MARLBOROUGH, Mass., Aug. 8, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced it has signed an agreement to acquire VENITI, Inc., a privately-held company in Fremont, California which has developed and commercialized the VICI VENOUS STENT® System for treating venous obstructive disease. Boston Scientific has been an investor in VENITI since 2016 and currently […]

InspireMD Reports 94% Increase in CGuard™ EPS Revenues for the Second Quarter of 2018

TEL AVIV, Israel, Aug. 06, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced results for the second quarter ending June 30, 2018. Second Quarter 2018 highlights: Revenues […]

CryoLife Reports Second Quarter 2018 Results

ATLANTA, Aug. 6, 2018 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today its financial results for the second quarter ended June 30, 2018. Second Quarter and Recent Business Highlights: Total revenues increased 43% to $68.5 million in the second quarter of 2018 compared to the second […]